miR‑138 modulates prostate cancer cell invasion and migration via Wnt/β‑catenin pathway

Yu,Zhongwei; Wang,Zulin; Li,Feng; Yang,Jiping; Tang,Laikun

doi:10.3892/mmr.2017.8273

miR‑138 modulates prostate cancer cell invasion and migration via Wnt/β‑catenin pathway

Authors:
- Zhongwei Yu
- Zulin Wang
- Feng Li
- Jiping Yang
- Laikun Tang
View Affiliations

Affiliations: Department of Urology, Eighth People's Hospital of Shanghai, Shanghai 200233, P.R. China
Published online on: December 12, 2017 https://doi.org/10.3892/mmr.2017.8273
Pages: 3140-3145

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis for prostate cancer patients with distant metastasis is poor, with an average survival rate of 24‑48 months. The exact mechanisms underlying prostate cancer metastasis remain to be elucidated, despite previous research efforts. The present study aimed to reveal the regulatory roles of miR‑138 via Wnt/β‑catenin pathway in prostate cancer cell migration and invasion. Reverse transcription‑quantitative polymerase chain reaction was used to examine the mRNA and protein expression levels and transwell assay was conducted to determine cell invasion and migration. A luciferase reporter assay was used to determine the target association between miR‑138 and β‑catenin. The present study identified microRNA (miR)‑138 as an invasion and migration regulator in prostate cancer. miR‑138 was downregulated in aggressive prostate cancer cell lines. Furthermore, followingmiR‑138 overexpression, prostate cancer cells exhibited impaired invasive and migratory abilities. E‑cadherin was upregulated and vimentin was downregulated. In addition, it was demonstrated that miR‑138 negatively regulated the Wnt/β‑catenin pathway activation in prostate cancer. The pathway was then activated via β‑catenin overexpression and this reversed the effects of miR‑138. The results suggest that miR‑138 downregulation may contribute to prostate cancer progression and metastasis. The findings provide a novel molecular therapeutic target in the treatment of prostate cancer metastasis.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R and Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer. 106:1624–1633. 2006. View Article : Google Scholar : PubMed/NCBI
3	Sturge J, Caley MP and Waxman J: Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol. 8:357–368. 2011. View Article : Google Scholar : PubMed/NCBI
4	Corn PG, Wang F, McKeehan WL and Navone N: Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res. 19:5856–5866. 2013. View Article : Google Scholar : PubMed/NCBI
5	Schoenborn JR, Nelson P and Fang M: Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 19:4058–4066. 2013. View Article : Google Scholar : PubMed/NCBI
6	Carthew RW and Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009. View Article : Google Scholar : PubMed/NCBI
7	Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B and Rigoutsos I: A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 126:1203–1217. 2006. View Article : Google Scholar : PubMed/NCBI
8	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
9	Liu X, Jiang L, Wang A, Yu J, Shi F and Zhou X: MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett. 286:217–222. 2009. View Article : Google Scholar : PubMed/NCBI
10	Jiang L, Dai Y, Liu X, Wang C, Wang A, Chen Z, Heidbreder CE, Kolokythas A and Zhou X: Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. Hum Genet. 129:189–197. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yamasaki T, Seki N, Yamada Y, Yoshino H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Nakagawa M and Enokida H: Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol. 41:805–817. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, et al: MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem. 31:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
15	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
16	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
17	Doolan G, Benke G and Giles G: An update on occupation and prostate cancer. Asian Pac J Cancer Prev. 15:501–516. 2014. View Article : Google Scholar : PubMed/NCBI
18	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
19	De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
20	Han RF, Ji X, Dong XG, Xiao RJ, Liu YP, Xiong J and Zhang QP: An epigenetic mechanism underlying doxorubicin induced EMT in the human BGC-823 gastric cancer cell. Asian Pac J Cancer Prev. 15:4271–4274. 2014. View Article : Google Scholar : PubMed/NCBI
21	Xu MM, Mao GX, Liu J, Li JC, Huang H, Liu YF and Liu JH: Low expression of the FoxO4 gene may contribute to the phenomenon of EMT in non-small cell lung cancer. Asian Pac J Cancer Prev. 15:4013–4018. 2014. View Article : Google Scholar : PubMed/NCBI
22	Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV and Dai Y: SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 31:4619–4629. 2012. View Article : Google Scholar : PubMed/NCBI
23	Hance MW, Dole K, Gopal U, Bohonowych JE, Jezierska-Drutel A, Neumann CA, Liu H, Garraway IP and Isaacs JS: Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 287:37732–37744. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, et al: Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 73:813–826. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zurita AJ, Bischoff FZ, Gorlov I, Mayer JN, Pircher TJ, Mikolajezyk S, Logothetis C and Lin SH: Cadherin-11 (Cad11) for detection of epithelial-mesenchymal transition (EMT) in circulating prostate cancer (PCa) cells. J Clin Oncol. 31:e220472013.
26	Yu CY, Liang GB, Du P and Liu YH: Lgr4 promotes glioma cell proliferation through activation of Wnt signaling. Asian Pac J Cancer Prev. 14:4907–4911. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yuan JB, Yang LY, Tang ZY, Zu XB and Qi L: Down-regulation of EZH2 by RNA interference inhibits proliferation and invasion of ACHN cells via the Wnt/β- catenin pathway. Asian Pac J Cancer Prev. 13:6197–6201. 2012. View Article : Google Scholar : PubMed/NCBI
28	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
29	Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, et al: Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model. Br J Cancer. 109:667–675. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yan Z, Zhu Z, Wang J, Sun J, Chen Y, Yang G, Chen W and Deng Y: Synthesis, characterization, and evaluation of a novel inhibitor of WNT/β-catenin signaling pathway. Mol Cancer. 12:1162013. View Article : Google Scholar : PubMed/NCBI
31	Basu D, Lettan R, Damodaran K, Strellec S, Reyes-Mugica M and Rebbaa A: Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 13:1457–1467. 2014. View Article : Google Scholar : PubMed/NCBI
32	Jiang Y, Dai J, Zhang H, Sottnik JL, Keller JM, Escott KJ, Sanganee HJ, Yao Z, McCauley LK and Keller ET: Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone. Mol Cancer Res. 11:1597–1610. 2013. View Article : Google Scholar : PubMed/NCBI